相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical experience with ZarzioA® in Europe: what have we learned?
Pere Gascon et al.
SUPPORTIVE CARE IN CANCER (2013)
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Thomas Pabst et al.
BLOOD (2012)
Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients
J-C Ianotto et al.
BONE MARROW TRANSPLANTATION (2012)
Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis
Julia Skokowa et al.
NATURE MEDICINE (2012)
Presently available biosimilars in hematology-oncology: G-CSF
Pere Gascon
TARGETED ONCOLOGY (2012)
Biosimilar rhG-CSFs: how similar are they?
Patricia Gravel et al.
TARGETED ONCOLOGY (2012)
First Experience of Autologous Peripheral Blood Stem Cell Mobilization with Biosimilar Granulocyte Colony-Stimulating Factor
Francois Lefrere et al.
ADVANCES IN THERAPY (2011)
Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association
Bronwen E. Shaw et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia
Matti Aapro et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
Cornelius F. Waller et al.
ANNALS OF HEMATOLOGY (2010)
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
Cornelius F. Waller et al.
ANNALS OF HEMATOLOGY (2010)
Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse
Stephanie Ehlers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer
Cornelius F. Waller et al.
ONKOLOGIE (2010)
The colony-stimulating factors and cancer
Donald Metcalf
NATURE REVIEWS CANCER (2010)
Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia
Cornelia Zeidler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Cost-Effectiveness of Pegfilgrastim Versus Filgrastim Primary Prophylaxis in Women With Early-Stage Breast Cancer Receiving Chemotherapy in the United States
Gary H. Lyman et al.
CLINICAL THERAPEUTICS (2009)
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
Ulrich Gatzemeier et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
A. Engert et al.
LEUKEMIA & LYMPHOMA (2009)
Choosing between GVHD and delayed engraftment
Paul J. Martin
NATURE MEDICINE (2009)
NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD+-sirtuin-1-dependent pathway
Julia Skokowa et al.
NATURE MEDICINE (2009)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells
Hyun Kyung Kim et al.
BLOOD (2006)
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation
HJ Khoury et al.
BLOOD (2006)
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death:: A study from the acute leukemia working party of the European Group for Blood and Marrow Transplantation
O Ringdén et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis
VT Ho et al.
BONE MARROW TRANSPLANTATION (2003)
分享论文
